巨食者受体类B型I的无活化促进了阿波利波蛋白E缺乏小鼠的动脉样硬化病变的发展
Wenwu Zhang1, Patricia G Yancey, Yan Ru Su
1Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Departments of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232-6300, USA.
Circulation
|October 29, 2003
概括
巨吸尘器受体类B型I (SR-BI) 表达保护小鼠免受动脉样硬化发展. 这一发现表明巨细胞SR-BI是预防和治疗动脉样硬化的潜在治疗标.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 代谢疾病 代谢疾病
背景情况:
- 拾荒受体类B型I (SR-BI) 存在于巨细胞中,可能有助于胆固醇排放.
- 目前,直接证据将巨细胞SR-BI表达与对动脉样硬化的保护联系在一起是有限的.
- 这项研究调查了巨细胞SR-BI在动脉样硬化中的体内作用,在阿波利波蛋白E缺陷小鼠模型中.
研究的目的:
- 确定巨SR-BI在体内对动脉样硬化病变发展的保护作用.
- 为了调查巨的SR-BI是否影响血脂质样本或胆固醇排放.
主要方法:
- 缺乏ApoE的小鼠从SR-BI-/- apoE-/-或SR-BI+/+ apoE-/-供体接受了骨髓移植.
- 接受者小鼠被食食12周以促进动脉样硬化.
- 大细胞SR-BI表达通过实时RT-PCR得到证实;动脉样硬化病变在主动脉中得到量化.
主要成果:
- 证实了成功的移植和巨细胞SR-BI的功能性失活.
- 血脂,脂蛋白分布或群体之间的高密度胆固醇亚群没有发现显著差异.
- 与对照组相比,缺乏巨细胞SR-BI的小鼠表现出大动脉动脉样硬化损伤面积增加了86%.
结论:
- 巨细胞SR-BI表达在apoE缺乏的小鼠中提供了对动脉样硬化的保护.
- 这种保护作用独立于血脂,高密度胆固醇或胆固醇流动的变化.
- 巨细胞SR-BI在体内表现出一种抗原作用,突出了其作为治疗点的潜力.
相关概念视频
01:38Inflammation
Overview
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...